YOLFTbeta
38

Next Biomedical Co.,Ltd.

389650 · KQ · Healthcare / Biotechnology

26,300.00KRW-1350.00 (-4.88%)

Price History

Full chart

Market Stats

Previous Close27,650.00
Open27,650.00
Day Range26,150.00 – 28,900.00
52-Week Range28,150.00 – 101,000.00
Volume22.18K
Market Cap260.47B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.80
50-Day Avg33,414.00
200-Day Avg55,734.00

About

Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Donhaeng Lee
  • Employees0
  • Headquarters6, Venture-ro 100beon-gil, Incheon, South Korea, 22013, Korea
  • Websitehttps://www.nextbiomedical.co.kr

Leadership

  • Mr. Donhaeng LeeCEO & Inside Director · b. 1963
  • Mr. YoonGu KangChief Financial Officer · b. 1977
  • Ms. Eunhye LeeMD & CTO · b. 1978
  • Mr. Cheoljung KangChief Scientific Officer & Executive Director · b. 1967
  • Ziv Haskal M.D.CMO
  • Joo Ha Hwang M.D., Ph.D.CMA
  • Mr. Chungryeol ChoiVP & Inside Director · b. 1960

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.27B2.80B4.88B9.54B16.48B
Growth (%)-+23.28%+74.67%+95.46%+72.67%
Cost of Revenue2.89B2.51B2.77B3.72B4.95B
Gross Profit-624.78M284.47M2.11B5.82B11.53B
Gross Margin-27.56%10.18%43.19%61.01%69.97%
Operating Expense6.35B5.15B9.76B4.31B12.25B
Operating Income-6.97B-4.86B-7.65B1.52B-719.54M
Operating Margin-307.42%-173.95%-156.73%15.88%-4.37%
EBITDA--4.91B-6.48B3.87B574.73M
EBITDA Margin--175.60%-132.72%40.58%3.49%
Net Income-16.64B-5.73B-7.52B2.86B-311.08M
Net Income Margin-734.13%-205.07%-154.06%29.97%-1.89%
R&D3.25B3.58B4.78B6.62B7.58B
R&D as % of Total Revenue143.12%128.04%97.97%69.40%46.01%
Interest Expense1.41B360.40M574.37M520.05M367.31M
Interest Expense % of Total Revenue62.31%12.89%11.76%5.45%2.23%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets39.72B32.14B29.64B58.84B59.27B
Total Liabilities34.64B32.39B35.54B13.65B11.16B
Total Equity5.08B-253.84M-5.90B45.19B48.11B
Cash22.02B491.00K262.00K308.00K6.79B
Net Debt-7.89B7.53B5.95B814.40M

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.40B-8.21B-4.16B-1.20B1.25B
Investing Cash Flow--10.94B4.11B-26.36B-
Financing Cash Flow-95.17M973.63M28.35B-
Capital Expenditure774.24M195.07M64.54M439.39M3.15B
Free Cash Flow-6.17B-8.40B-4.22B-1.64B-1.90B
FCF to OCF114.35%102.38%101.55%136.60%-152.11%

Earnings

Report DateSep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------
EPS Actual-166.9417.75-52.01-111.14130.60-6.07-17.79-76.68
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap260.47B
Enterprise Value240.15B
Trailing P/E0.00
Forward P/E0.00
Price / Sales14.64
Price / Book5.46
Revenue (TTM)17.79B
Gross Profit (TTM)12.48B
EBITDA-1.76B
Profit Margin1.31%
Operating Margin-20.95%
Return on Equity0.49%
Return on Assets-2.34%
Shares Outstanding8.20M
Shares Float5.64M
Beta-0.80
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%